Exploring Key Insights of the Enbrel Market: Growth Prospects, Emerging Trends, and Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the enbrel market right now?
The marketplace for Enbrel has shown a strong increase in recent years. From 2024 to 2025, it is expected to expand from $15,876.25 million to $16,825.42 million, representing a compound annual growth rate (CAGR) of 6.0%. Several factors have driven such growth in the past, including increasing occurrences of rheumatoid arthritis, increased interest in customized therapies for autoimmune disorders, heightened demand for advanced biologic treatments, growing investments in biologics within healthcare, and the aging population.
How fast Is the enbrel market expected to grow, and what’s its future value?
We anticipate robust expansion of the Enbrel market size in the approaching years. The market is projected to escalate to $20,930.93 million in 2029, with a compound annual growth rate (CAGR) of 5.6%. This imminent growth during the forecast period is attributed to the escalating utilisation of Enbrel for a variety of indications, an increase in backing from the government for biologics and treatment of rheumatoid arthritis (RA), an increased understanding of autoimmune diseases, rising knowledge about inflammatory diseases in the populace, wider availability of biosimilars, and increased consciousness about the benefits of Enbrel. The forecast period will highlight major trends such as the use of digital healthcare tools for managing autoimmune diseases, global collaborations among pharmaceutical companies, the creation of long-acting injectable formulations for improved patient compliance, the use of artificial intelligence in drug development for autoimmune diseases, and the development of alternative delivery methods for biologic drugs.
Get your enbrel market report here!
https://www.thebusinessresearchcompany.com/report/enbrel-global-market-report
What are the leading drivers of growth in the enbrel market?
The rise in autoimmune diseases is anticipated to fuel the expansion of the enbrel market. Autoimmune diseases are conditions where the immune system falsely assaults the body’s healthy cells and tissues, resulting in inflammation and damage to various organs. The uptick in these diseases can be linked to factors like genetic factors, environmental influences, and shifts in lifestyle and immune system behavior. The increased incidence of autoimmune diseases escalates the need for treatments such as Enbrel that can help control inflammatory conditions like rheumatoid arthritis and psoriatic arthritis. As an example, the National Library of Medicine, an American medical library, reported in August 2022 that there were approximately 928 autoimmune cases related to the COVID-19 vaccine that year. Out of these, 81.5% (756 cases) were newly diagnosed autoimmune diseases, typically appearing eight days after vaccination. The majority of those affected were women (53.6%), with a median age of 48. Therefore, the booming incidence of autoimmune diseases will bolster the enbrel market.
What are the key segments defining the enbrel market?
The enbrel market covered in this report is segmented –
1) By Product: Injectable Solution; Prefilled Syringes; Combination Therapy; Extended Release Formulations; Biosimilars
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Application: Rheumatoid Arthritis; Juvenile Idiopathic Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Other Applications
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20451&type=smp
Who are the key players steering the development of the enbrel market?
Major companies operating in the enbrel market are Amgen Inc.
What emerging trends are influencing the growth of the enbrel market?
A predominant trend in the Enbrel market involves garnering drug approval from regulatory bodies to secure a competitive position within the industry. Approval involves the endorsement of a new medication’s safety, effectiveness, and quality by regulatory authorities, after evaluation of clinical trial data. As an example, in October 2023, Amgen Inc., a biopharmaceutical firm based in the U.S., received approval from the U.S. Food and Drug Administration (FDA) for Enbrel’s use in the treatment of children aged two and above suffering from active juvenile psoriatic arthritis (JPsA). This endorsement underscores the unique capacity of etanercept as a tumor necrosis factor blocker, as proven by extensive efficacy and safety studies in adults with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and psoriasis. The approval also included pharmacokinetic (PK) data, which validates its use in pediatric patients suffering from active juvenile idiopathic arthritis (JIA) and psoriasis. The prescribed dosage of juvenile PsA (JPsA) is adjusted according to body weight and delivered through a weekly subcutaneous injection.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20451
Which regions are most influential in expanding the enbrel market?
North America was the largest region in the enbrel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the enbrel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Inflammatory Bowel Disease Treatment Global Market Report 2025
Non-Steroidal Anti-inflammatory Drugs Global Market Report 2025
Anti-Inflammatory Therapeutics Global Market Report 2025
https://thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
